Reading: True / False / Not Given: Question 3

Maggot debridement therapy, sometimes referred to as biosurgery, uses the larvae of certain fly species (most commonly the green bottle fly, Lucilia sericata) to clean chronic wounds that have failed to heal through conventional treatment. Sterile larvae, bred under laboratory conditions to eliminate any risk of introducing infection, are applied directly to a wound and either left loose beneath a permeable dressing or contained within a small mesh bag secured over the affected area. Over the following two to four days, the larvae feed selectively on dead and infected tissue while leaving healthy tissue largely undisturbed, a targeted feeding behaviour that distinguishes the treatment from surgical debridement, in which a clinician manually removes damaged tissue with a scalpel and cannot always avoid also removing some healthy tissue in the process.

The therapy's revival in modern medicine followed a period of decline after the introduction of antibiotics in the mid-twentieth century, when maggot treatment was largely abandoned in favour of pharmaceutical alternatives that seemed to make an insect-based method unnecessary. Renewed clinical interest emerged from the 1990s onward, driven partly by rising concern about bacteria resistant to standard antibiotics and partly by a series of clinical trials suggesting that larvae not only remove dead tissue efficiently but may also secrete substances with antimicrobial properties and compounds that appear to stimulate the growth of new tissue at the wound site.

Despite this renewed interest, maggot debridement therapy remains a minority treatment in most healthcare systems. Surveys of clinicians frequently cite patient reluctance as the principal barrier to wider adoption; many patients report finding the idea of live larvae on their skin distressing, even after being shown evidence of the treatment's effectiveness, and some clinics have found that patients withdraw consent once the dressing is removed and the larvae become visible. Cost is a secondary consideration in some healthcare settings, since sterile larvae must be produced and shipped under controlled conditions with a short shelf life, though this expense is frequently offset by shorter overall treatment times and reduced need for surgical intervention compared with conventional wound care.

Do the following statements agree with the information given in the passage? Write TRUE, FALSE or NOT GIVEN.

1. Lucilia sericata is the fly species most commonly used in maggot debridement therapy.
2. The larvae used in this therapy feed indiscriminately on both healthy and dead tissue.
3. Surgical debridement using a scalpel always avoids removing any healthy tissue.
4. Maggot therapy was continuously used throughout the twentieth century without any decline in popularity.
5. Some studies suggest that larvae secrete substances that may help fight microbes.
6. Patient reluctance is identified as the main barrier to wider adoption of maggot therapy in clinician surveys.
7. The specific antimicrobial compounds secreted by the larvae have been chemically identified and named in clinical trials.
8. The cost of producing sterile larvae has decreased significantly over the past decade.